PMV Pharmaceuticals, Inc.(PMVP)Earnings, Financials & Key RatiosPMV Pharmaceuticals, Inc. (PMVP) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company faces an imminent liquidity shortfall risk given that cash reserves have dwindled to $39.1 million against a quarterly operating cash burn of $19.7 million.
PMV Pharmaceuticals, Inc. (PMVP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
PMV Pharmaceuticals, Inc. (PMVP) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.34vs $0.41+17.1% | — |
| Q2 2026 | Mar 6, 2026 | $0.34vs $0.40+15.0% | — |
| Q4 2025 | Nov 12, 2025 | $0.40vs $0.40+0.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.41vs $0.39-5.1% | — |
Recent stock market news and headlines for PMV Pharmaceuticals, Inc. (PMVP)
PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Key metrics vs top competitors for PMV Pharmaceuticals, Inc. (PMVP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.24 | $66.13M | -0.84 | — | — | -55.37% | — | |
| $1.92 | $15.61M | -1.60 | — | -90182.27% | — | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $30.12 | $3.5B | -34.62 | 48.29% | -188.15% | -41.54% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — |
PMV Pharmaceuticals, Inc. (PMVP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PMV Pharmaceuticals, Inc. (PMVP) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 12, 2026·SEC
Mar 6, 2026·SEC
Nov 12, 2025·SEC
Get notified when PMVP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PMV Pharmaceuticals, Inc. (PMVP) stock FAQ — growth, dividends, profitability & financials explained
PMV Pharmaceuticals, Inc. (PMVP) reported a net loss of $78.3M for fiscal year 2025.
PMV Pharmaceuticals, Inc. (PMVP) has a return on equity (ROE) of -55.4%. Negative ROE indicates the company is unprofitable.
PMV Pharmaceuticals, Inc. (PMVP) had negative free cash flow of $75.0M in fiscal year 2025, likely due to heavy capital investments.
